AVTX
NASDAQ · Biotechnology
Avalo Therapeutics Inc
$18.88
-0.57 (-2.93%)
Financial Highlights (FY 2026)
Revenue
243.2K
Net Income
-322,715,665
Gross Margin
100.0%
Profit Margin
-132,642.4%
Rev Growth
-85.2%
D/E Ratio
0.03
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 58.1% | 58.1% |
| Operating Margin | -123,601.7% | -111,241.6% | 21.6% | 19.4% |
| Profit Margin | -132,642.4% | -126,010.3% | 22.3% | 22.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 243.2K | 1.64M | 36.29M | 36.66M |
| Gross Profit | 243.2K | 1.64M | 21.09M | 21.30M |
| Operating Income | -300,625,266 | -1,823,199,052 | 7.82M | 7.11M |
| Net Income | -322,715,665 | -1,957,170,475 | 8.09M | 8.22M |
| Gross Margin | 100.0% | 100.0% | 58.1% | 58.1% |
| Operating Margin | -123,601.7% | -111,241.6% | 21.6% | 19.4% |
| Profit Margin | -132,642.4% | -126,010.3% | 22.3% | 22.4% |
| Rev Growth | -85.2% | -85.2% | +16.8% | -1.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 14.21M | 14.21M | 45.39M | 52.32M |
| Total Equity | 507.61M | 507.61M | 96.06M | 95.40M |
| D/E Ratio | 0.03 | 0.03 | 0.47 | 0.55 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -299,300,109 | -1,916,004,740 | 9.50M | 9.77M |
| Free Cash Flow | — | — | 4.67M | 3.24M |